Successful Treatment of Intractable Hemothorax with Recombinant Factor Ⅶa in a Nonhemophilic Patient

• Published in: Journal of the Formosan Medical Association 2006-09, Vol.105 (9), p.765-769
• Main Authors: Wei, Yu-Feng, Ho, Chao-Chi, Lin, Ming-Tzer, Yuan, Ang, Yu, Chong-Jen
• Format: Article
• Language: English
• Subjects: Aged; Chronic Disease; Drug Administration Schedule; Factor VII - administration & dosage; Factor VIIa; Female; Hemothorax - drug therapy; Hepatitis C - complications; Humans; Liver Cirrhosis - etiology; Recombinant Proteins - administration & dosage
• ISSN: 0929-6646
• DOI: 10.29828/JFMA.200609.0011

Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment. We report a case of catastrophic hemothorax in which bleeding was stopped by administration of rFVIIa. A 68-year-old woman with chronic hepatitis C-related liver cirrhosis was admitted due to pneumonia and parapneumonic effusion. The patient developed hemothorax and hypovolemic shock after thoracentesis. Conventional therapies including tube thoracostomy and transarterial embolization failed to stop the life-threatening bleeding. The bleeding stopped after administration of rFVIIa 100 microg/kg/BW at 2-hour intervals for a total of two doses on the 3rd day of hospitalization. Despite intensive care, however, the patient died due to nosocomial infection and multiple organ failure on the 12th day of hospitalization. Hemothorax in a nonhemophilic patient can be successfully treated with rFVIIa.